About to buy some $NVO (+1,79 %) ahead of results. The stock is down ~36% in the past year and trades at just 12x forward P/E — historically cheap for a company with 33% net margins and 60% ROE.
They beat estimates in 3 of the last 4 quarters, the GLP-1 market is still massive, and yesterday's positive data on oral semaglutide in kids is a nice catalyst going in.
Main risks I see: $LLY (+5,92 %) competition and the recent revenue slowdown (-7.6% QoQ).
Do you think they'll beat on May 6th? Anyone else positioned here? 👇
